Literature DB >> 18314349

A step-wise approach significantly enhances protein yield of a rationally-designed agonist antibody fragment in E. coli.

Bing Lin1, Mark W Renshaw, Kathleen Autote, Lynette M Smith, Peter Calveley, Katherine S Bowdish, Shana Frederickson.   

Abstract

Fab59 is a rationally-designed antibody fragment (Fab) that mimics the activity of the cytokine thrombopoietin (TPO). Fab59 activity was initially detected directly from bacterial supernatants in a cell-based assay and was subsequently estimated to be equipotent to TPO using purified material. However, the expression of Fab59 was insufficient to support in vivo characterization of the Fab due to extremely low expression levels from its initial phage display expression vector. To boost expression, a new expression vector was designed and constructed, and Fab59 light chain codons were optimized for bacterial expression. However, from this a new challenge arose, in that the codon-optimized Fab59 was more toxic to Escherichia coli cells than parental Fab59. Co-expression of the bacterial chaperon protein Skp alleviated this toxicity. A two-step purification method was used to isolate monomeric Fab59 from the periplasm. Although Fab59 was prone to form aggregates during the purification process, buffer modification efficiently eliminated this problem. Overall, optimization of Fab59 expression and purification achieved a 100-fold increase in Fab59 production in E. coli relative to the starting yield. The yield of purified monomeric Fab59 from a shake flask reached up to 3.5mg/L, which was sufficient to support testing of the agonist activity of purified monomeric Fab59 in vivo. Even higher yields may be achieved by purification of Fab present in the culture media, as Skp most significantly increased accumulation of Fab59 in that location.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18314349     DOI: 10.1016/j.pep.2008.01.002

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  8 in total

1.  Oligovalent Fab display on M13 phage improved by directed evolution.

Authors:  Tuomas Huovinen; Hanna Sanmark; Jani Ylä-Pelto; Markus Vehniäinen; Urpo Lamminmäki
Journal:  Mol Biotechnol       Date:  2010-03       Impact factor: 2.695

Review 2.  The pharmacology and clinical application of thrombopoietin receptor agonists.

Authors:  Caizheng Li; Li Zheng
Journal:  Int J Hematol       Date:  2014-09-18       Impact factor: 2.490

3.  Comprehensive engineering of Escherichia coli for enhanced expression of IgG antibodies.

Authors:  Tomohiro Makino; Georgios Skretas; Tae-Hyun Kang; George Georgiou
Journal:  Metab Eng       Date:  2010-12-03       Impact factor: 9.783

4.  Effect of DNA sequence of Fab fragment on yield characteristics and cell growth of E. coli.

Authors:  Antti Kulmala; Tuomas Huovinen; Urpo Lamminmäki
Journal:  Sci Rep       Date:  2017-06-19       Impact factor: 4.379

5.  Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli.

Authors:  Ario de Marco
Journal:  Microb Cell Fact       Date:  2009-05-14       Impact factor: 5.328

6.  Use of folding modulators to improve heterologous protein production in Escherichia coli.

Authors:  Olga Kolaj; Stefania Spada; Sylvain Robin; J Gerard Wall
Journal:  Microb Cell Fact       Date:  2009-01-27       Impact factor: 5.328

Review 7.  Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.

Authors:  Mohamed A Alfaleh; Hashem O Alsaab; Ahmad Bakur Mahmoud; Almohanad A Alkayyal; Martina L Jones; Stephen M Mahler; Anwar M Hashem
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561

Review 8.  Phage Display Libraries for Antibody Therapeutic Discovery and Development.

Authors:  Juan C Almagro; Martha Pedraza-Escalona; Hugo Iván Arrieta; Sonia Mayra Pérez-Tapia
Journal:  Antibodies (Basel)       Date:  2019-08-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.